By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Silexion Therapeutics Ltd. (SLXN)

NASDAQ Currency in USD
$4.93
+$0.44
+9.80%
Last Update: 11 Sept 2025, 20:00
$2.77M
Market Cap
1.69
P/E Ratio (TTM)
Forward Dividend Yield
$3.11 - $63.45
52 Week Range

SLXN Stock Price Chart

Explore Silexion Therapeutics Ltd. interactive price chart. Choose custom timeframes to analyze SLXN price movements and trends.

SLXN Company Profile

Discover essential business fundamentals and corporate details for Silexion Therapeutics Ltd. (SLXN) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

16 Aug 2024

Employees

11.00

CEO

Ilan Hadar

Description

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

SLXN Financial Timeline

Browse a chronological timeline of Silexion Therapeutics Ltd. corporate events including earnings releases, dividend announcements, and stock splits.

Earnings released on 12 Aug 2025

EPS came in at -$4.32 falling short of the estimated -$3.15 by -37.14%.

Stock split effective on 29 Jul 2025

Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 13 May 2025

EPS came in at -$3.90 falling short of the estimated -$0.22 by -1.67K%.

Earnings released on 18 Mar 2025

EPS came in at -$20.76 falling short of the estimated -$0.98 by -2.02K%.

Stock split effective on 29 Nov 2024

Shares were split 1 : 9 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 14 Nov 2024

EPS came in at -$18.27 falling short of the estimated -$7.38 by -147.56%.

Earnings released on 13 Aug 2024

EPS came in at -$0.99 .

Earnings released on 15 May 2024

SLXN Stock Performance

Access detailed SLXN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run